Aligos Therapeutics Q3 net loss narrows on lower R&D costs
Overview
US biotech firm's Q3 net loss and loss per share both beat analyst expectations
Operating expenses fell yr/yr, mainly due to lower R&D costs for hepatitis B trial
Outlook
Aligos anticipates cash and investments will fund operations into Q1 2027
Result Drivers
LOWER R&D COSTS - Co said decrease in R&D expenses was mainly due to reduced third-party costs for pevifoscorvir sodium Phase 2 trial
TRIAL ENROLLMENT COMPLETE - Co said enrollment for Phase 2 B-SUPREME study of pevifoscorvir sodium is complete
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | Beat | $2.09 | $2.17 (7 Analysts) |
Q3 Net Loss | Beat | $21.86 mln | $24.74 mln (7 Analysts) |
Q3 Income From Operations | Beat | -$21.89 mln | -$25.33 mln (7 Analysts) |
Q3 Pretax Loss | Beat | $21.53 mln | $24.73 mln (7 Analysts) |
Q3 Operating Expenses | $24.76 mln |
Reuters Recommended Reads
Nov 5 - Janux Therapeutics Q3 net loss narrows on lower R&D expenses
Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows
Nov 4 - Kailera Therapeutics Q3 net loss widens on higher R&D costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)